About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Employees: 5,400
Price: $137.88
Previous close: $136.49
Market capitalization: $9.45B
Volume: 1,021,304
P/E ratio: 25.46
52-week low: $126.40
52-week high: $354.88

Additional performance and financial-statement views load in the interactive application.

Market information is provided for research and visualization and is not investment advice.